Your browser doesn't support javascript.
loading
Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch, Paul Giacomo; Plage, Henning; Hofbauer, Sebastian; Kornienko, Kira; Weinberger, Sarah; Roßner, Florian; Schallenberg, Simon; Kluth, Martina; Lennartz, Maximilian; Blessin, Niclas C; Marx, Andreas H; Samtleben, Henrik; Fisch, Margit; Rink, Michael; Slojewski, Marcin; Kaczmarek, Krystian; Ecke, Thorsten; Hallmann, Steffen; Koch, Stefan; Adamini, Nico; Minner, Sarah; Simon, Ronald; Sauter, Guido; Zecha, Henrik; Klatte, Tobias; Schlomm, Thorsten; Horst, David; Elezkurtaj, Sefer.
Afiliação
  • Bruch PG; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Plage H; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Hofbauer S; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Kornienko K; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Weinberger S; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Roßner F; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Schallenberg S; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Kluth M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lennartz M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Blessin NC; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Marx AH; Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
  • Samtleben H; Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
  • Fisch M; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Rink M; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Slojewski M; Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland.
  • Kaczmarek K; Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland.
  • Ecke T; Department of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
  • Hallmann S; Department of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
  • Koch S; Department of Pathology, Helios Hospital Bad Saarow, Bad Saarow, Germany.
  • Adamini N; Department of Urology, Albertinen Hospital, Hamburg, Germany.
  • Minner S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: R.Simon@uke.de.
  • Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Zecha H; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; Department of Urology, Albertinen Hospital, Hamburg, Germany.
  • Klatte T; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Schlomm T; Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Horst D; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Elezkurtaj S; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Exp Mol Pathol ; 131: 104860, 2023 06.
Article em En | MEDLINE | ID: mdl-36997051
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Exp Mol Pathol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Exp Mol Pathol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Holanda